Bionano Genomics Inc. (BNGO): What Technical Indicators Show

Bionano Genomics Inc. (NASDAQ:BNGO) saw an upside of 0.48% to $5.18 after adding $0.02 on Monday. The 5-day average trading volume is 6,065,264 shares of the company’s common stock. It has gained $5.53 in the past week and touched a new high 1 time within the past 5 days. An average of 6,973,061 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 7,419,550.

BNGO’s 1-month performance is -2.46% or -$0.35 on its low of $4.92 reached on 10/07/21. The company’s shares have touched a 52-week low of $0.47 and high of $15.69, with the stock’s rally to the 52-week high happening on 02/16/21. YTD, BNGO has achieved 67.53% or $2.13 and has reached a new high 8 times. However, the current price is down -66.95%% from the 52-week high price.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


Valuation Metrics

Bionano Genomics Inc. (BNGO) has a trailing price-to-earnings (P/E) ratio of 26.50 for the broader industry and 32.44 for the sector.BNGO stock has a beta of 0.00. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 112.93 while the price-to-book (PB) in the most recent quarter is 4.16.

Bionano Genomics Inc.’s quick ratio for the period ended June 29 was 31.40, with the current ratio over the same period at 31.90 meaning that BNGO stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.00, while the total debt to equity was 0.00. In terms of profitability, the gross margin trailing 12 months is 33.30%. The trailing 12-month EBITDA margin is -418.40%. The firm’s gross profit as reported stood at $2.77 million against revenue of $8.5 million.

Earnings Surprise

For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 57.05% to -$18.79 million, while revenue of -$9.95 million was 47.05% off the previous quarter. Analysts expected BNGO to announce -$0.04 per share in earnings in its latest quarter, but it posted -$0.07, representing a -75.00% surprise. EBITDA for the quarter stood at more than -$15.96 million. BNGO stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 10.94 million. Shareholders hold equity totaling $279.14 million

Technical Picture

Let’s look briefly at Bionano Genomics Inc. (BNGO) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 15 October was 46.85% to suggest the stock is trending Neutral, with historical volatility in this time period at 41.86%.

The stock’s 5-day moving average is $5.29, reflecting a +1.96% or $0.10 change from its current price. BNGO is currently trading +0.77% above its 20-day SMA, -13.46% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -17.56% and +69.16% respectively.

Stochastic %K and %D was 44.65% and 50.80% and the average true range (ATR) pointed at 0.26. The RSI (14) points at 46.26%, while the 14-day stochastic is at 42.65% with the period’s ATR at 0.27. The stock’s 9-day MACD Oscillator is pointing at 0.03 and 0.03 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for Bionano Genomics Inc. (NASDAQ: BNGO), BTIG Research launched coverage with a Buy rating. Analysts offering their rating for BNGO stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate BNGO as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 4 have offered a “buy” rating.

What is BNGO’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $10.00 and a high of $14.00, with their median price target at $12.00. Looking at these predictions, the average price target given by analysts is for Bionano Genomics Inc. (BNGO) stock is $12.00.


Please enter your comment!
Please enter your name here


Hot Topics

Related Videos

Related Videos

Related Articles



Download Free eBook For



100% free. stop anytime no spam